

Screening Checklist for the 3rd dose of mRNA COVID-19 Immunization for Immunocompromised People based on CDC recommendations

- Did the patient receive and complete either of the mRNA vaccines (2 doses of Pfizer or Moderna)
 - Yes
 - No → **not eligible**

There is currently no evidence to make a recommendation for patients who received the Johnson & Johnson vaccine. For patients who have only received one dose of an mRNA vaccine (Pfizer or Moderna), schedule or encourage them to walk-in to receive their second dose.

To be eligible for a third dose, the patient must have ONE of the following:

- Currently receiving active cancer treatment for tumors or cancers of the blood?
 - Yes
 - No → continue below
- Received an organ transplant and are taking medicine to suppress the immune system (see common medications on next page)
 - Yes
 - No → continue below
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system (see common medications on next page)
 - Yes
 - No → continue below
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
 - Yes
 - No → continue below
- Advanced or untreated HIV infection
 - Yes
 - No → continue below
- Active treatment with high-dose corticosteroids or other drugs that may suppress the immune system (see common medications on next page)
 - Yes
 - No → **not eligible**
 -

**** If eligible, remind the patient to take their vaccine card to their appointment to document receiving the 3rd vaccination****

Table with example medications on the following page

Screening Checklist for the 3rd dose of mRNA COVID-19 Immunization for Immunocompromised People based on CDC recommendations

Common Immunosuppressive Medications Table

Table does not contain all immunosuppressive medications, consult physician, pharmacy students/pharmacists and/or LexiComp as needed

Immunosuppressants	Tumor Necrosis Factor (TNF) Blockers	High Dose Corticosteroids	Transplant Medications	Other Rheumatologic Medications and Janus Kinase Inhibitors
Azathioprine Basiliximab- (Simulect) Cyclophosphamide Methotrexate Mycophenolate- (CellCept, Myfortic) Rituximab- (Rituxan)	Adalimumab- (Humira) Certolizumab- (Cimzia) Etanercept- (Enbrel) Golimumab- (Simponi) Infliximab- (Remicade)	Prednisone - 15-20mg/day for ≥ 2-4 weeks OR 1-1.5mg/kg/day Dexamethasone - 0.4-0.8 mg/kg/day	Cyclosporine- (Gengraf, Neoral, Sandimmune) Tacrolimus- (Prograf) Sirolimus- (Rapamune) Everolimus-(Zortress, Afinitor) Belatacept- (Nulojix)	Abatacept (Orencia) Anakinra (Kineret) Baricitinib (Olmiant) Leflunomide (Arava) Sarilumab (Kevzara) Tocilizumab (Actemra) Tofacitinib (Xeljanz) Upadacitinib (Rinvoq)

Developed By: Nathaniel Lampton and Vance Howerton on August 17, 2021
Doctor of Pharmacy Candidates Class of 2022
University of Missouri - Kansas City

- COVID-19 vaccines for moderately to severely immunocompromised people. Centers for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>. Accessed August 17, 2021.